THNR Amplify Weight Loss Drug & Treatment ETF Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
Feed
19:09
Sep 14
Sep 14
Massive unmet need, only 46M served
Obesity, diabetes, and cardiovascular disease represent a massive unmet need, with roughly one billion people suffering from obesity, 500 million from diabetes, and 500 million from cardiovascular disease, while Novo currently serves only 46 million patients. The future market opportunity is very large and vast.
HIGH
About THNR Investor Commentary
Across the available history and selected sources, Buzzberg tracks THNR (Amplify Weight Loss Drug & Treatment ETF) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Past 7 days, before deduplication: 1 bullish. Latest voices: Mike Doustdar.